Modified vaccinia ankara virus variant and cultivation method

Details Modified vaccinia ankara virus variant and cultivation method Modified vaccinia ankara virus variant and cultivation method

2011-06-21

2011-06-21

Lucas, Zachariah (Department: 1648)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Avian cell, per se

C424S093700, C424S184100, C424S232100, C424S281100, C424S093600, C435S041000, C435S070100, C435S235100, C435S239000, C435S384000

Reexamination Certificate

active

07964395

ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

REFERENCES:
patent: 3887430 (1975-06-01), Torney et al.
patent: 4072565 (1978-02-01), Weiss et al.
patent: 5024947 (1991-06-01), Inlow et al.
patent: 5155020 (1992-10-01), Paoletti
patent: 5185146 (1993-02-01), Altenburger
patent: 5403582 (1995-04-01), Nazerian et al.
patent: 5405772 (1995-04-01), Ponting
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5550051 (1996-08-01), Mundt et al.
patent: 5753489 (1998-05-01), Kistner et al.
patent: 5756341 (1998-05-01), Kistner et al.
patent: 5789245 (1998-08-01), Dubensky et al.
patent: 6100061 (2000-08-01), Reiter et al.
patent: 6146873 (2000-11-01), Kistner et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 6924137 (2005-08-01), Howley et al.
patent: 7056723 (2006-06-01), Heller et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 7189536 (2007-03-01), Chaplin et al.
patent: 7335364 (2008-02-01), Chaplin et al.
patent: 7384644 (2008-06-01), Chaplin et al.
patent: 7445924 (2008-11-01), Chaplin et al.
patent: 7695939 (2010-04-01), Rathe et al.
patent: 2002/0022268 (2002-02-01), Xu et al.
patent: 2003/0013190 (2003-01-01), Mayr
patent: 2003/0228330 (2003-12-01), Falkner et al.
patent: 2004/0058441 (2004-03-01), Pain et al.
patent: 2004/0234950 (2004-11-01), Howley et al.
patent: 2005/0214323 (2005-09-01), Chaplin et al.
patent: 2005/0214324 (2005-09-01), Rathe et al.
patent: 2006/0093620 (2006-05-01), Falkner et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2008/0089907 (2008-04-01), Chaplin et al.
patent: 2010/0111999 (2010-05-01), Guehenneux et al.
patent: 0584788 (1994-03-01), None
patent: H9-154571 (1997-06-01), None
patent: WO 92/05246 (1992-04-01), None
patent: 95/22978 (1995-08-01), None
patent: WO96/15231 (1996-05-01), None
patent: WO 97/02355 (1997-01-01), None
patent: WO 97/02355 (1997-02-01), None
patent: WO 97/31119 (1997-08-01), None
patent: WO 98/04680 (1998-02-01), None
patent: WO 98/15614 (1998-04-01), None
patent: WO98/15614 (1998-04-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/07869 (1999-02-01), None
patent: WO 00/28016 (2000-05-01), None
patent: WO 00/29428 (2000-05-01), None
patent: WO 01/68820 (2001-09-01), None
patent: WO 01/89559 (2001-11-01), None
patent: WO 02/24224 (2002-03-01), None
patent: WO02/24876 (2002-03-01), None
patent: WO 02/42480 (2002-05-01), None
patent: WO03/008533 (2003-01-01), None
patent: 03/054175 (2003-07-01), None
patent: WO03/054174 (2003-07-01), None
Cubitt and Barrett, Propagation and Preliminary Characterization of a Chicken Candidate Calicivirus, 1985, Journal of General Virology, vol. 66, pp. 1431-1438.
Balk et al., Epidermal growth factor and insulin cause normal chicken heart mesenchymal cells to proliferate like their Rous sarcoma virus-infected counterparts, Proc. Nat. Acad. Sci. USA 79: 1154-1157 (1982).
Couchman et al.,Fibronectin Has a Dual Role in Locomotion and Anchorage of Primary Chick Fibroblasts and Can Promote Entry into the Division Cycle, J. Cell. Biol. 93: 402-410 (1982).
Kwon et al., Test on Growth and Maintenance Examination of Chick Embryo Fibroblast in the Medium to Which Chicken Embryo Amnio-Allantoic Fluid is Added Instead of Bovine Serum, Agriculture Test Research Report No. 20 (Livestock Hygiene Sericulture Section): 5-9 (1978).
Nakamura et al., Tyrosine Phosphorylation of Specific Proteins After Mitogen Stimulation of Chicken Embryo Fibroblasts, Mol. Cell Biol. 3:380-390 (1983).
Pietrzkowski et al., Cellular Activities Associated with the Transition of Chick Embryo Fibroblasts from Stationary to Proliferation State, Folia Histochemica et Cytobiologica vol. 27:183-196 (1969).
Price et al., Serum-Free Medium Without Animal Components for Virus Production, FOCUS vol. 19 No. 3, 67-69 (1997).
Zell-Und Gewebekultur, Einfithrung in die Grundlagen sowie ausgewählte Methoden and Anwendungen, Lindl et al., Gustav Fischer Verlag, Stuttgart, New York, p. 57 (1987).
Life Technologies, Product description of VP-SFM (May 1999).
Focus on Alternatives, Serum Free Media for Cell Culture (Aug. 2006).
Geistlich and Gehring, Isolation and characterization of a novel type of growth factor derived from serum-free conditioned medium of chicken embryo fibroblasts, European Journal of Biochemistry 207: 147-153, 1992.
Grob et al., Role of the Individual Interferon Systems and Specific Immunity in Mice in Controlling Systemic Dissemination of Attenuated Pseudorabies Virus Infection, 1999, Journal of Virology, vol. 73, No. 6, pp. 4748-4754.
Carroll, MW, and Moss, B. 1997, Virology 238:198-211.
Meyer, H, et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72:1031-1038.
Marhoul, Z, et al. Cultivation of Lednice (Yaba1) virus in goose, duck and chick embryo cells. 1976, Acta Virol. 20:499-505. (Abstract).
Ivanov, I, et al. Propagation of avian pox virus vaccine strains in duck embryo cell line—DEC 99., 2001, Experimental Pathology and Parasitology 4/6, pp. 46-49.
Asher D.M., Bovine Sera Used in the Manufacture of Biologicals: Current Concerns and Policies of the U.S. Food and Drug Administration Regarding the Transmissible Spongiform Encephalopathies, 1999, Developments in Biological Standardization, vol. 99, pp. 41-44.
Kozak et al., Transmissible Spongiform Encephalopathies (TSE): Minimizing the Risk of Transmission of Biological/Biopharmaceutical Products: an Industry Perspective, 1996, Developments in Biological Standardization, vol. 88, pp. 257-264.
Pietrzkowski, et al. “Dextran T-500 improves survival and spreading of chick embryo cells in serum-free medium” Folia Histochemica Et Cytobiologica, vol. 26 No. 3, 1988, p. 123-132.
Stittelaar, et al., Vaccine 19: 3700-3709, 2001.
Sutter and Moss, Proc. Natl. Acad. Sci. USA 89:10847-51, 1992.
Schiefiinger, et al., Proc. Natl. Acad. Sci. USA 89:9977-81, 1992.
Merchlinsky, et al., Virology 190:522-6, 1992.
Moss, et al. “Host range restricted, non-replicating vaccinia vires vectors as vaccine candidates.” Advances in Experimentaly Medicine and Biology, 397:7-13, 1996.
Wyatt, et al., PNAS 101:4590-4595, 2004.
Earl, et al., Nature 428: 182-185, 2004.
A. Mayr, ZBL VET B 23, 417-430 (1976).
Blanchard, JT, et al., Journal of General Virology, 79, 1159-1167, 1998.
Bender, et al. Journal of Virology, vol. 70, No. 9, p. 6418-6424, 1996.
Schneider, et al. Nature Medicine, 4, 397-402, 1998.
Sutter, et al. Vaccine 12, 1032-1040, 1994.
Eo, et al., The Journal of Immunology 166: 54735479, 2001.
Holzer, et al., Journal of Virology 73: 4536-4542, 1998.
Antoine, et al., Virology 244: 365-396, 1998.
Gilbert, et al., Biol. Chem. 380: 299-303, 1999.
Behera, et al., Hum. Gene Ther. 13 (14): 1697-709, 2002.
Belyakov, et al., Proc. Natl. Acad. Sci. 100: 9458-9463, 2003.
Hanke, et al., Journal of Viroogy 73: 7524-7532, 1999.
Dollenmeier et al, Proliferation and Differentiation of Chick Skeletal Muscle Cells Cultured in a Chemically Defined Medium, Exp. Cell. Res. 135:47-61 (1981).
Gospodarowicz et al., Growth Factors in Mammalian Cell Culture, Annu. Rev.

Affiliated with

Also associated with

Rating

Modified vaccinia ankara virus variant and cultivation method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified vaccinia ankara virus variant and cultivation method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia ankara virus variant and cultivation method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2630535